Skripsi
GAMBARAN SKOR FIBROSIS-4 (FIB-4) PADA PASIEN SIROSIS HEPATIS KARENA HEPATITIS B DI RSUP DR. MOHAMMAD HOESIN PALEMBANG TAHUN 2023
Background: Hepatic cirrhosis is a late-stage pathologic condition of liver damage. Diagnosis of fibrosis progression as early as possible is necessary to prevent disease progression to hepatic cirrhosis and to support patient prognosis. In the diagnosis of hepatic cirrhosis, the FIB-4 score is one of the non-invasive biomarkers that is easy to perform through its simple examination. Previous studies that specifically tested the FIB-4 score of patients with hepatic cirrhosis due to hepatitis B are still very limited. This study aims to determine the description of the FIB-4 score in patients with hepatic cirrhosis due to hepatitis B at Dr. Mohammad Hoesin Hospital Palembang in 2023. Methods: This study is an observational descriptive study using the total sampling method with the calculation of the minimum sample formula. Secondary research data were taken from the medical records of patients with hepatic cirrhosis due to hepatitis B at Dr. Mohammad Hoesin Hospital Palembang in 2023 by fulfilling the inclusion and exclusion criteria. Results: A total of 95 samples with fulfillment of the inclusion and exclusion criteria of the study, patients with fibrosis-4 (FIB-4) scores in the high risk group leading to advanced fibrosis (>3.25) were 56.8%. The highest frequency refers to each parameter of fibrosis-4 (FIB-4) score calculation, namely the age group 35-65 years (92.6%), AST levels >35 U/L (65.3%), ALT levels 7-56 U/L (84.2%), and platelet levels 400,000/mm3 (66.3%). Conclusion: Patients with hepatic cirrhosis due to hepatitis B who had a FIB-4 score with a high risk group interpretation were the most frequent (56.8%).
| Inventory Code | Barcode | Call Number | Location | Status |
|---|---|---|---|---|
| 2407006765 | T160933 | T1609332024 | Central Library (REFERENCE) | Available but not for loan - Not for Loan |
No other version available